Home » Stocks » SYBX

Synlogic, Inc. (SYBX)

Stock Price: $3.09 USD -0.33 (-9.65%)
Updated May 6, 2021 4:00 PM EDT - Market closed
After-hours: $3.15 +0.06 (1.94%) May 6, 4:59 PM
Market Cap 173.16M
Revenue (ttm) 545,000
Net Income (ttm) -59.17M
Shares Out 35.84M
EPS (ttm) -1.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 6
Last Price $3.09
Previous Close $3.42
Change ($) -0.33
Change (%) -9.65%
Day's Open 3.40
Day's Range 3.08 - 3.40
Day's Volume 277,515
52-Week Range 1.78 - 5.11

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Penny stocks are very risky, which is why they have such low prices. Many of the companies in this risky part of the market will go bankrupt.

Other stocks mentioned: ABEO, FBIO
2 weeks ago - Benzinga

Many penny stocks are destined for bankruptcy, but there are some that will survive. Wall Street thinks these companies are undervalued.

Other stocks mentioned: ABEO, CTIC, EFOI, FBIO, IO, PXLW
2 weeks ago - InvestorPlace

Analysts say these penny stocks are a buy right now & have bullish price targets to boot. The post Penny Stocks To Buy According To Analysts With Price Targets Up to 341% appeared first on Penny Stocks ...

Other stocks mentioned: EVGN, PAVM, SVRA
2 weeks ago - PennyStocks

CAMBRIDGE, Mass., April 16, 2021 /PRNewswire/ -- Synlogic (Nasdaq: SYBX) a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the pricing of i...

2 weeks ago - PRNewsWire

CAMBRIDGE, Mass., April 15, 2021 /PRNewswire/ -- Synlogic (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it has com...

3 weeks ago - PRNewsWire

CAMBRIDGE, Mass., April 13, 2021 Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data from the Phase 1 stu...

3 weeks ago - PRNewsWire

CAMBRIDGE, Mass., April 10, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today presented data on S...

3 weeks ago - PRNewsWire

CAMBRIDGE, Mass., April 1, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife...

1 month ago - PRNewsWire

CAMBRIDGE, Mass., March 25, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported financial ...

1 month ago - PRNewsWire

CAMBRIDGE, Mass., March 24, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that SYNB...

1 month ago - PRNewsWire

CAMBRIDGE, Mass., March 16, 2021 /PRNewswire/ -- Synlogic, Inc. (NASDAQ: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Compa...

1 month ago - PRNewsWire

CAMBRIDGE, Mass., Feb. 15, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife...

2 months ago - PRNewsWire

CAMBRIDGE, Mass., Feb. 2, 2021 /PRNewswire/ -- A collaboration between MIT Voigt Lab and Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biolog...

3 months ago - PRNewsWire

Investors need to pay close attention to Synlogic (SYBX) stock based on the movements in the options market lately.

3 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Jan. 11, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today outlined significant...

3 months ago - PRNewsWire

Even as the broader market trades higher in reaction to the availability of the first coronavirus vaccine under emergency use authorization, a slew of biopharma stocks are moving on company-specific upd...

Other stocks mentioned: ANPC, ARPO, ARVN, VERU
4 months ago - Benzinga

CAMBRIDGE, Mass., Dec. 14, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced SYNB1891 h...

4 months ago - PRNewsWire

CAMBRIDGE, Mass., Dec. 9, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the appoint...

4 months ago - PRNewsWire

CAMBRIDGE, Mass., Dec. 7, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it wil...

4 months ago - PRNewsWire

Synlogic (SYBX) saw a big move last session, as its shares jumped nearly 13% on the day, amid huge volumes.

5 months ago - Zacks Investment Research

CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that Aoife...

5 months ago - PRNewsWire

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Shares of Synlogic (NASDAQ:SYBX) moved higher by 10.11% in pre-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 7.69% year over year to ($0.36), which b...

6 months ago - Benzinga

CAMBRIDGE, Mass., Nov. 5, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today reported financial re...

6 months ago - PRNewsWire

CAMBRIDGE, Mass., Oct. 27, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the Compan...

6 months ago - PRNewsWire

CAMBRIDGE, Mass., Oct. 22, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced that it wi...

6 months ago - PRNewsWire

CAMBRIDGE, Mass., Sept. 14, 2020 /PRNewswire/ -- Synlogic, Inc.

7 months ago - PRNewsWire

CAMBRIDGE, Mass., Sept. 8, 2020 /PRNewswire/ -- Synlogic, Inc.

7 months ago - PRNewsWire

With a low capital cost and solid growth potential, many investors prefer to invest in penny stocks. Here are the top stocks to buy this year.

Other stocks mentioned: CWBHF, GNUS, OGI, WTRH
8 months ago - InvestorPlace

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

CAMBRIDGE, Mass., July 30, 2020 /PRNewswire/ -- Synlogic, Inc.

9 months ago - PRNewsWire

CAMBRIDGE, Mass., July 28, 2020 /PRNewswire/ -- Synlogic, Inc.

9 months ago - PRNewsWire

CAMBRIDGE, Mass., June 1, 2020 /PRNewswire/ -- Synlogic, Inc., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announc...

11 months ago - PRNewsWire

CAMBRIDGE, Mass., May 21, 2020 /PRNewswire/ -- Synlogic (Nasdaq: SYBX) announced today that the company will host a Virtual R&D Event at 12:30 pm ET on Wednesday, May 27th, 2020. The event will provide ...

11 months ago - PRNewsWire

CAMBRIDGE, Mass., May 21, 2020 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announc...

11 months ago - PRNewsWire

Synlogic: A Clinical-Stage Biopharma With A Good Risk/Reward Ratio

11 months ago - Seeking Alpha

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Shares of Synlogic (NASDAQ:SYBX) rose 2.7% in pre-market trading after the company reported Q1 results.

11 months ago - Benzinga

The COVID-19 pandemic has changed normal operations for companies across the world as they cope with resource limitations, health precautions and other challenges.

Other stocks mentioned: AVRO, FATE, KNSA, MRSN, NVCR, ORTX, TCRR
1 year ago - 24/7 Wall Street

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

As of late, it has definitely been a great time to be an investor in Synlogic.

1 year ago - Zacks Investment Research

With stocks at all time highs and after the Dow rose more than 22% and the S&P 500 rose over 28% in 2019, many investors have yet to make many changes in the portfolios for what could be another solid 2...

Other stocks mentioned: CGEN, GLUU, GME, GRPN, IDXG, MEET, OGI ...
1 year ago - 24/7 Wall Street

As of late, it has definitely been a great time to be an investor Synlogic

1 year ago - Zacks Investment Research

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q3 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Synlogic (SYBX) discontinues the development of its early-stage pipeline candidate, SYNB1020, for the treatment of hyperammonemia, following disappointing study results.

1 year ago - Zacks Investment Research

Shares of Synlogic Inc. SYBX, +4.77% sank 9.3% toward a record low in premarket trading Tuesday, after the biotechnology company said it has discontinued the development of SYNB1020 for the treatment of...

1 year ago - Market Watch

Synlogic, Inc. (SYBX) CEO Aoife Brennan on Q2 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Synlogic, Inc. (SYBX) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

1 year ago - Zacks Investment Research

Synlogic (NASDAQ: SYBX) reported positive data from Phase 1/2a study of SYNB1618 in patients with Phenylketonuria.

1 year ago - Benzinga

Ginkgo Bioworks and Synlogic to collaborate on 'living medicine'

YouTube video

Bioengineers are reprogramming bacteria in our bodies to create living medicine.

1 year ago - CNBC Television

About SYBX

Synlogic, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its therapeutic programs include SYNB1618, an oral therapy that is in Phase II clinical trial to treat phenylketonuria (PKU), as well as pre-clinical stage product SYNB1934 for the treatment of PKU; and SYNB8802 that is in Phase I clinical trial for the treatment of Enteric Hyperoxaluria. The company is also developing SYNB1891, an intratumo... [Read more...]

Industry
Biotechnology
CEO
Aoife Brennan
Employees
72
Stock Exchange
NASDAQ
Ticker Symbol
SYBX
Full Company Profile

Financial Performance

In 2020, Synlogic's revenue was $545,000, a decrease of -75.49% compared to the previous year's $2.22 million. Losses were -$59.17 million, 15.2% more than in 2019.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for Synlogic stock is "Buy." The 12-month stock price forecast is 10.71, which is an increase of 246.60% from the latest price.

Price Target
$10.71
(246.60% upside)
Analyst Consensus: Buy